Study guide

13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules

NCRA Oncology Data Specialist ODS-C

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters

1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish

2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws

2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority

3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance

3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance

4 Chapter 4: Registry Organization, Staffing & Information Systems

4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning

5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement

5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)

6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality

6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)

7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics

7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data

8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer

8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors

9 Chapter 9: Casefinding & Reportability

9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"

10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators

10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More

11 Chapter 11: Class of Case, Key Dates & Case Identifiers

11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them

12 Chapter 12: Follow-Up, Vital Status & Recurrence

12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary

13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade

13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables

14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules

14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules

15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018

15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples

16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS

16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation

13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules

Key Takeaways Explain This Topic AI

A morphology code has a four-digit histology code and a one-digit behavior code: /0 benign, /1 uncertain or borderline, /2 in situ, /3 malignant primary site; /6 (metastatic) and /9 (uncertain whether primary or metastatic) are not used in registry abstracts.

The Solid Tumor Rules say to code the histology diagnosed before neoadjuvant therapy, to code the histology assigned by the physician, and never to change histology to make a case stageable.

The histology rules are hierarchical within the Single Tumor and Multiple Tumors sections: use the first rule that applies and stop.

A histology described by ambiguous terms (for example "consistent with") is coded only if a physician clinically confirms it, the patient is treated for it, or it is the only histology information for an accessioned case.

Borderline ovarian tumors (/1) have not been reportable to SEER, NPCR or CoC since 2001, while non-malignant CNS tumors (/0, /1) have been reportable since 2004.

Last updated: September 2026

Structure of a morphology code

  • Part Example 8500/3 Item
  • Four-digit histology 8500 = invasive carcinoma of no special type (duct) Histologic Type ICD-O-3 [522]
  • Behavior digit /3 = malignant, primary site Behavior Code ICD-O-3 [523]

The first three digits group related tumors. For example, 814x–838x are adenocarcinomas, 805x–808x are squamous cell carcinomas, 872x–879x are nevi and melanomas, 959x–972x are lymphomas, and 980x–994x are leukemias. The fourth digit gives the specific type.

Behavior codes

  • Code Meaning Registry use
  • /0 Benign Reportable only for brain and CNS sites diagnosed in 2004 or later

/1 Uncertain whether benign or malignant; borderline; low malignant potential Reportable for CNS sites (2004+); most others are not reportable. Some /1 heme diseases were reclassified as /3 and are reportable

/2 In situ; intraepithelial; noninfiltrating; noninvasive Reportable, with exceptions: keratinocyte-type skin tumors (C44, 8000–8110) are never reportable, and CoC does not require cervical CIS/CIN III, PIN III, VIN III, VAIN III or AIN III, although SEER still collects some of these (see Section 9.3)

  • /3 Malignant, primary site Reportable (except basal and squamous cell skin cancers of C44)
  • /6 Malignant, metastatic site Not used in registry abstracts: code the primary with /3
  • /9 Malignant, uncertain whether primary or metastatic Not used in registry abstracts

Matrix concept: ICD-O's rule is to use the appropriate behavior digit with a histology code even if that exact combination is not printed in the book. For example, a pathologist's "in situ" diagnosis of a type listed only as /3 is coded /2. Registries then apply edits and the NAACCR update tables, which state which new combinations are valid and reportable.

Reportability by behavior: common traps

Borderline ovarian tumors (for example, serous borderline tumor 8442/1) are not reportable to SEER, NPCR or CoC for 2001 and later diagnoses. Invasive ovarian carcinoma is /3.

Non-malignant CNS tumors such as meningioma 9530/0 and vestibular schwannoma 9560/0 are reportable for 2004 and later diagnoses (Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act).

GIST and thymoma: /3 for 2021 and later diagnoses.

Pilocytic astrocytoma: coded 9421/1 for 2023 and later, and still reportable as a CNS tumor.

Microinvasion means invasion, so the behavior is /3 .

A single tumor with in situ and invasive components is coded to the invasive histology with behavior /3.

ICD-O-3.2 and the annual update tables

North American registries adopted ICD-O-3.2 for cases diagnosed in 2021 and later. Each year NAACCR publishes the Guidelines for ICD-O-3.2 Histology Code and Behavior Update , which lists new codes, new terms and changes in behavior and reportability for that diagnosis year. The Solid Tumor Rules editors recommend coding histology using, in order: the Solid Tumor Rules , then the updated ICD-O histology tables , then ICD-O-3.2 itself. If a code still cannot be found, submit a question to Ask a SEER Registrar .

General histology rules (Solid Tumor Rules)

Do not use the histology rules to decide reportability.

Rules are split into Single Tumor and Multiple Tumors Abstracted as a Single Primary sections. Within each, the rules are hierarchical: use the first rule that applies and stop .

Code the histology diagnosed before neoadjuvant therapy. Chemotherapy, radiation, immunotherapy and targeted therapy can change the tumor's appearance. The exception: if the first diagnosis came from FNA, cytology, or a regional or metastatic site, and the resection after neoadjuvant therapy shows a different or more specific histology, code the resection histology.

Code the histology assigned by the physician. Do not change histology to make a case fit a staging schema.

Priority of documentation: each site module lists its own priority. Tissue pathology from the primary site comes first: addenda and comments, then the final diagnosis or synoptic report, then the CAP protocol. Cytology, imaging and physician statements come after that. When the final diagnosis and the synoptic report differ, use the more specific histology.

Most specific histology: code a subtype or variant (Table 3 "column 3" terms in each module) over its NOS parent. For example, invasive lobular carcinoma 8520/3 rather than carcinoma NOS. When a biopsy and a resection give two clearly different histologies, code the histology from the most representative specimen , meaning the one with more tumor.

Combination codes: some modules provide combination codes for specific mixtures. For example, breast carcinoma NST (duct) with lobular carcinoma is 8522 , and the last-resort breast code for mixed subtypes is 8255 . Adenosquamous carcinoma is 8560/3 , and mixed adenoneuroendocrine carcinoma is 8244/3 . Use a combination code only when the module's table lists that combination.

Histology described with ambiguous terms

The Solid Tumor Rules list of ambiguous terms for histology is: apparently, appears, comparable with, compatible with, consistent with, favor(s), malignant appearing, most likely, presumed, probable, suspect(ed), suspicious (for), and typical (of).

A histology described with one of these terms is coded only when:

  • the histology is clinically confirmed by a physician (attending, pathologist, oncologist and so on); or
  • the patient is treated for that histology; or

the case is accessioned based on that single ambiguous histology , with no other histology information.

Otherwise, code the NOS histology. The Solid Tumor Rules also stress that the SEER and CoC ambiguous-terms lists decide reportability (Section 9.4), not histology .

Examples from the breast module:

"Carcinoma NST consistent with pleomorphic carcinoma," and the oncology consult says pleomorphic carcinoma: code pleomorphic carcinoma , because it is clinically confirmed.

"Sarcoma consistent with liposarcoma," and the treatment plan is for liposarcoma: code liposarcoma , because the patient is treated for it.

An outpatient biopsy says "probably apocrine carcinoma," and no further information is available: code apocrine carcinoma , because it is the only histology for the accessioned case.

Worked examples

Pathology Code Reason

Breast: invasive carcinoma NST, 2.1 cm, with DCIS 8500/3 Single tumor with in situ and invasive parts, so code the invasive

Bladder TURBT: noninvasive papillary urothelial carcinoma, high grade 8130/2 In situ (noninvasive) urothelial carcinoma is reportable

Ovary: serous borderline tumor 8442/1 Not reportable (2001+)

Rectum: biopsy adenocarcinoma; after chemoradiation, resection shows "mucinous features, treatment effect" 8140/3 Code the histology before neoadjuvant therapy

Lung: resection "adenocarcinoma, most likely enteric type," with no clinical confirmation or specific treatment 8140/3 The ambiguous specific histology fails the conditions, so code the NOS

Loading diagram... Coding a solid tumor histology